[go: up one dir, main page]

ZA200903335B - Amino nicotinic and isonicotinic acid derivatives as DHODH inhibitors - Google Patents

Amino nicotinic and isonicotinic acid derivatives as DHODH inhibitors

Info

Publication number
ZA200903335B
ZA200903335B ZA200903333A ZA200903335A ZA200903335B ZA 200903335 B ZA200903335 B ZA 200903335B ZA 200903333 A ZA200903333 A ZA 200903333A ZA 200903335 A ZA200903335 A ZA 200903335A ZA 200903335 B ZA200903335 B ZA 200903335B
Authority
ZA
South Africa
Prior art keywords
acid derivatives
isonicotinic acid
dhodh inhibitors
amino nicotinic
nicotinic
Prior art date
Application number
ZA200903333A
Other languages
English (en)
Inventor
Palomino Laria Julio Cesar Castro
Sola Montserrat Erra
Toribio Maria Estrella Lozoya
Romero Eloisa Navarro
Original Assignee
Almirall Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200701086A external-priority patent/ES2327372B1/es
Application filed by Almirall Lab filed Critical Almirall Lab
Publication of ZA200903335B publication Critical patent/ZA200903335B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
ZA200903333A 2006-12-22 2009-05-14 Amino nicotinic and isonicotinic acid derivatives as DHODH inhibitors ZA200903335B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200603250A ES2319596B1 (es) 2006-12-22 2006-12-22 Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
ES200701086A ES2327372B1 (es) 2007-04-23 2007-04-23 Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.

Publications (1)

Publication Number Publication Date
ZA200903335B true ZA200903335B (en) 2010-06-30

Family

ID=39319647

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200903333A ZA200903335B (en) 2006-12-22 2009-05-14 Amino nicotinic and isonicotinic acid derivatives as DHODH inhibitors

Country Status (31)

Country Link
US (2) US8258308B2 (da)
EP (1) EP2121614B1 (da)
JP (1) JP5318776B2 (da)
KR (1) KR101435233B1 (da)
CN (1) CN101589025B (da)
AR (1) AR064444A1 (da)
AU (1) AU2007338321B2 (da)
BR (1) BRPI0717697B1 (da)
CA (1) CA2674512C (da)
CL (1) CL2007003666A1 (da)
CY (1) CY1113687T1 (da)
DK (1) DK2121614T3 (da)
EC (1) ECSP099395A (da)
ES (2) ES2319596B1 (da)
HR (1) HRP20120697T1 (da)
IL (1) IL199188A (da)
ME (1) ME01475B (da)
MX (1) MX2009006408A (da)
MY (1) MY153393A (da)
NO (1) NO341991B1 (da)
NZ (1) NZ577017A (da)
PE (1) PE20081846A1 (da)
PL (1) PL2121614T3 (da)
PT (1) PT2121614E (da)
RS (1) RS52514B (da)
RU (1) RU2469024C2 (da)
SI (1) SI2121614T1 (da)
TW (1) TWI405572B (da)
UY (1) UY30794A1 (da)
WO (1) WO2008077639A1 (da)
ZA (1) ZA200903335B (da)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
ES2327372B1 (es) * 2007-04-23 2010-08-24 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP2135610A1 (en) * 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009313053A1 (en) * 2008-11-07 2010-05-14 4Sc Ag Combinational therapy comprising DHODH inhibitor and methotrexate for treating autoimmune disease
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
EP2226323A1 (en) 2009-02-27 2010-09-08 Almirall, S.A. New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2228367A1 (en) * 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
TWI530286B (zh) * 2009-05-04 2016-04-21 帕納特斯製藥格斯有限公司 作為抑制病毒化合物之抗發炎劑
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
KR20120107080A (ko) 2009-11-27 2012-09-28 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
EP2360158A1 (en) 2010-02-18 2011-08-24 Almirall, S.A. Pyrazole derivatives as jak inhibitors
EP2380890A1 (en) 2010-04-23 2011-10-26 Almirall, S.A. New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
EP2394998A1 (en) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
EP2397482A1 (en) 2010-06-15 2011-12-21 Almirall, S.A. Heteroaryl imidazolone derivatives as jak inhibitors
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
EP2444086A1 (en) 2010-10-22 2012-04-25 Almirall, S.A. Combinations comprising DHODH inhibitors and COX inhibitors
EP2444088A1 (en) 2010-10-22 2012-04-25 Almirall, S.A. Amino derivatives for the treatment of proliferative skin disorders
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
EP2455081A1 (en) 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of crohn's disease
EP2455080A1 (en) 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
US10016402B2 (en) 2011-02-08 2018-07-10 Children's Medical Center Corporation Methods for treatment of melanoma
WO2012109329A2 (en) 2011-02-08 2012-08-16 Children's Medical Center Corporation Methods for treatment of melanoma
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
EP2594271A1 (en) 2011-11-21 2013-05-22 Almirall, S.A. 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid for the treatment of psoriasis.
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
AU2013339167B2 (en) * 2012-10-31 2018-03-15 Fujifilm Corporation Novel amine derivative or salt thereof
UY35332A (es) 2013-02-15 2014-11-28 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
AU2014352920A1 (en) 2013-11-22 2016-06-23 Genzyme Corporation Novel methods for treating neurodegenerative diseases
CA2944570A1 (en) 2014-04-11 2015-10-15 Panoptes Pharma Gmbh Anti-inflammatory agents as virostatic compounds
ES2960598T3 (es) 2014-05-08 2024-03-05 Kiora Pharmaceuticals Gmbh Compuestos para el tratamiento de enfermedades y trastornos oftálmicos
WO2016200778A1 (en) * 2015-06-08 2016-12-15 Children's Medical Center Corporation Methods for treatment of melanoma
WO2016202800A1 (en) 2015-06-16 2016-12-22 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
MX390363B (es) 2016-06-10 2025-03-20 Boehringer Ingelheim Int Combinacion de linagliptina y metformina
WO2018136009A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
WO2018136010A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
US11311548B2 (en) 2017-03-02 2022-04-26 Aslan Pharmaceuticals Pte. Ltd. Cancer therapy
EP3589286B1 (en) 2017-03-02 2022-08-03 ASLAN Pharmaceuticals Pte Ltd Dhodh inhibitor for treating haematological cancer
CN108524482B (zh) * 2017-03-02 2022-11-25 中国科学院上海药物研究所 2-(取代苯氨基)苯甲酸类fto抑制剂治疗白血病的用途
JP6978251B2 (ja) * 2017-03-03 2021-12-08 アスラン ファーマシューティカルズ ピーティーイー リミテッド がん治療
WO2018222134A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
WO2018222135A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
EP3761960B1 (en) 2018-03-09 2023-11-22 Kiora Pharmaceuticals GmbH Ophthalmic formulation
JP7126556B2 (ja) 2018-09-28 2022-08-26 富士フイルム株式会社 シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤
WO2020130077A1 (ja) 2018-12-21 2020-06-25 国立大学法人北海道大学 多能性幹細胞を除去するための組成物、及び多能性幹細胞の除去方法
EP3750892A1 (en) 2019-06-14 2020-12-16 Yerevan State University Novel 5-cyclopropyl-furo[3,4-c]pyridine-3,4(1h,5h)-dione 1,1' substituted derivatives and their uses
EP4052760B1 (en) 2019-10-31 2024-03-13 FUJIFILM Corporation Pyrazine derivative or salt thereof, and use of same
CN116056766A (zh) * 2020-07-30 2023-05-02 富士胶片株式会社 含氮杂环化合物或其盐、其利用以及其中间体
KR20230116779A (ko) * 2020-10-15 2023-08-04 아슬란 파마슈티컬스 피티이 엘티디 디히드로오로테이트 헤하이드로즈네이즈(dhodh) 저해제를 이용한 자가면역 질환의 치료
CN116940359A (zh) * 2020-10-15 2023-10-24 亚狮康私人有限公司 用二氢乳清酸脱氢酶（dhodh）抑制剂治疗自身免疫病
EP4362968A4 (en) * 2021-06-30 2025-07-23 Ohio State Innovation Foundation METHODS AND COMPOSITIONS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD47-SIRPA THERAPEUTIC AGENT
CN118613472A (zh) * 2022-01-31 2024-09-06 新前沿生物公司 基于烟酸酯和烟酰胺核苷的化合物及其衍生物
WO2023149841A1 (en) * 2022-02-03 2023-08-10 Aslan Pharmaceuticals Pte Ltd Dhodh inhibitor polymorph
WO2025215126A1 (en) 2024-04-12 2025-10-16 Immunic Ag Synthesis of vidofludimus and its calcium salt

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US529490A (en) * 1894-11-20 hegg-em
EP0008532B1 (en) * 1978-08-22 1983-07-20 Sumitomo Chemical Company, Limited Synthesis of amines
JPH05331163A (ja) * 1991-03-26 1993-12-14 Kumiai Chem Ind Co Ltd ピリジン誘導体及び除草剤
ES2167377T3 (es) * 1993-10-01 2002-05-16 Novartis Ag Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
ATE209518T1 (de) 1995-06-21 2001-12-15 Asta Medica Ag Arzneipulverkartusche mit integrierter dosiereinrichtung, sowie pulverinhalator
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
DE19610955A1 (de) * 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
GB9804343D0 (en) 1998-02-27 1998-04-22 Univ Cardiff Chemical compounds
SK17632001A3 (sk) * 1999-06-10 2003-03-04 Warner-Lambert Company Liečivo na liečbu Alzheimerovej choroby, inhibíciu agregácie amyloidového proteínu a spôsob na zobrazenie depozít amyloidu
PT1381356E (pt) 2001-04-05 2008-07-24 Aventis Pharma Inc Utilização de (4' -trifluorometilfenil) - amida do ácido (z) -2- ciano-3-hidroxi-but-2-enóico para tratamento da esclerose múltipla
PE20030120A1 (es) * 2001-06-19 2003-02-12 Merck & Co Inc Sal amina de un antagonista de receptor de integrin
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
MXPA04000224A (es) * 2001-07-10 2005-07-25 4Sc Ag Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US7258118B2 (en) * 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
PE20040844A1 (es) 2002-11-26 2004-12-30 Novartis Ag Acidos fenilaceticos y derivados como inhibidores de la cox-2
US7071355B2 (en) 2002-12-23 2006-07-04 4 Sc Ag Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO2004056747A1 (en) * 2002-12-23 2004-07-08 4Sc Ag Dhodh-inhibitors and method for their identification
SE0400234D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New compounds, methods for their preparation and use thereof
BRPI0511290A (pt) 2004-05-21 2007-12-18 Uab Research Foundation composições e métodos referentes aos inibidores da sìntese da pirimidina
WO2006022442A1 (ja) * 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
WO2006044741A1 (en) 2004-10-19 2006-04-27 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
PT1802579E (pt) * 2004-10-20 2014-02-17 Merck Serono Sa Derivados da 3-arilaminopiridina
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
NZ579040A (en) 2007-02-06 2011-01-28 Chelsea Therapeutics Inc New compounds, methods for their preparation and use thereof
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2210615A1 (en) 2009-01-21 2010-07-28 Almirall, S.A. Combinations comprising methotrexate and DHODH inhibitors
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid

Also Published As

Publication number Publication date
TW200833332A (en) 2008-08-16
ME01475B (me) 2014-04-20
US8258308B2 (en) 2012-09-04
SI2121614T1 (sl) 2012-10-30
CY1113687T1 (el) 2016-06-22
AU2007338321A1 (en) 2008-07-03
ES2319596B1 (es) 2010-02-08
EP2121614B1 (en) 2012-06-20
NO341991B1 (no) 2018-03-12
CN101589025B (zh) 2012-05-30
ES2389785T3 (es) 2012-10-31
US20120294854A1 (en) 2012-11-22
RU2009127847A (ru) 2011-01-27
KR101435233B1 (ko) 2014-08-28
DK2121614T3 (da) 2012-09-17
PL2121614T3 (pl) 2012-11-30
RU2469024C2 (ru) 2012-12-10
ECSP099395A (es) 2009-07-31
NO20092380L (no) 2009-07-14
KR20090090352A (ko) 2009-08-25
PE20081846A1 (es) 2008-12-27
JP2010513362A (ja) 2010-04-30
PT2121614E (pt) 2012-08-31
CA2674512A1 (en) 2008-07-03
US20100074898A1 (en) 2010-03-25
RS52514B (sr) 2013-04-30
AR064444A1 (es) 2009-04-01
TWI405572B (zh) 2013-08-21
HRP20120697T1 (hr) 2012-09-30
BRPI0717697B1 (pt) 2022-05-03
JP5318776B2 (ja) 2013-10-16
BRPI0717697A2 (pt) 2016-03-22
CA2674512C (en) 2015-09-08
UY30794A1 (es) 2008-05-31
WO2008077639A1 (en) 2008-07-03
US8691852B2 (en) 2014-04-08
CL2007003666A1 (es) 2008-07-04
CN101589025A (zh) 2009-11-25
MX2009006408A (es) 2009-06-23
NZ577017A (en) 2011-12-22
MY153393A (en) 2015-02-13
EP2121614A1 (en) 2009-11-25
ES2319596A1 (es) 2009-05-08
HK1133014A1 (en) 2010-03-12
IL199188A (en) 2014-06-30
AU2007338321B2 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
ZA200903335B (en) Amino nicotinic and isonicotinic acid derivatives as DHODH inhibitors
AU2009226958A8 (en) Pyridines and pyrazines as inhibitors of PI3K
PL2178840T3 (pl) Pochodne kwasu azabifenyloaminobenzoesowego jako inhibitory dhodh
IL212670A0 (en) Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
IL198171A0 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
IL242267A0 (en) Solid citrate and tartrate salts of iv– dpp inhibitors
SI2094703T1 (sl) Amidi diazabicikloalkanov, selektivni za nikotinski acetilholinski receptorski podtip
IL205176A0 (en) Pyridazinone derivatives and use thereof as p2x7 receptor inhibitors
IL216132A (en) Heterocyclic carboxamide diamine compounds, their uses and their medicinal products and inhibitors
EP2188295A4 (en) PYRIDINE DERIVATIVES AND METHODS OF USE
IL198487A0 (en) 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
ZA200808364B (en) 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors
PT2069335E (pt) Derivados de piridin-3-ilo como agentes imunomoduladores
PL2004155T3 (pl) Inhibitory agregacji białek
EP2076128A4 (en) PROTEIN CHINESE INHIBITOR AND ITS USE METHOD
EP2360155A4 (en) 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT
IL210412A0 (en) Heterocyclic derivatives and uses thereof
SI2252597T1 (sl) Derivati pirazina in njihova uporaba kot inhibitorji protein kinaze
IL198398A0 (en) 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
IL194932A0 (en) N-(2-thiazolyl)-amide derivatives as gsk-3 inhibitors
ZA201008609B (en) Heterocyclic urea derivatives and methods of use thereof
ATE530529T1 (de) 5-phenyl-nicotinsäureamid-derivate
EP2083826A4 (en) PYRIMIDINE DERIVATIVES AS POSH AND POSH-AP HEMMER
TWI372762B (en) Amino derivatives of b-homoandrostanes and b-heteroandrostanes
GB0602780D0 (en) Amino Acid Derivatives